Aurobindo Pharma Limited has informed the Exchange about Incorporation of new wholly owned subsidiary in India
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma has set up a new wholly owned subsidiary called Engenra Biologics Private Limited in India, incorporated on February 24, 2026. The new entity will operate in the pharmaceuticals sector, with the purpose of expanding Aurobindo's contract manufacturing and other pharmaceutical manufacturing operations. Aurobindo has subscribed 100% of the share capital in cash, with an initial investment of Rs. 10 lakhs (1,00,000 equity shares of Rs. 10 each). The promoters and promoter group have no direct interest in the new entity, and no government or regulatory approvals were required for this incorporation.
This is a small, routine corporate restructuring move with minimal financial impact given the modest initial capital of Rs. 10 lakhs. It signals Aurobindo's intent to scale up its contract manufacturing and biologics capabilities, but is unlikely to move the stock price meaningfully on its own.